Chemo-Emboli zation for Head and Neck Cancer

Palo Alto (17 mi)

Overseen byJesse Jones, MD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: University of Alabama at Birmingham

Stay on your current meds

No Placebo Group

Prior Safety Data

Approved in 4 jurisdictions

Trial Summary

What is the purpose of this trial?The study will evaluate whether adjuvant chemo-embolization increases progression free and/or overall survival relative to standard of care radiation and chemo- and/or immunotherapy in cisplatin-ineligible head and neck cancer patients with an acceptable morbidity rate.

Eligibility Criteria

This trial is for adults over 18 with squamous cell carcinoma of the head and neck who can't use cisplatin due to certain health issues like kidney, nerve, or ear problems. They must be able to have chemo-embolization, follow study rules, and plan standard cancer treatments. Pregnant women and those unfit for the procedure are excluded.

Inclusion Criteria

I have been diagnosed with squamous cell carcinoma in my head or neck.

I cannot receive platinum-based chemotherapy due to kidney, nerve, or ear problems, or because my physical health status is limited.

I am fit for chemo-embolization treatment.

Exclusion Criteria

I cannot undergo chemo-embolization due to my health condition.

Treatment Details

The study tests if adding chemo-embolization to usual cancer care (radiation plus chemotherapy/immunotherapy) helps patients live longer without their cancer getting worse compared to just standard care in those who cannot tolerate cisplatin.

1Treatment groups

Experimental Treatment

Group I: Chemo-embolizationExperimental Treatment1 Intervention

Intra-arterial Cisplatin suspension 150-300 mg is infused into the tumor pedicle(s)

Cisplatin is already approved in European Union, United States, Canada, Japan for the following indications:

🇪🇺 Approved in European Union as Platinol for: